Seminars in Nephrology
Volume 27, Issue 2 , Pages 237-247 , March 2007

Genetics of Diabetic Nephropathy: Lessons From Mice

References 

  1. USRDS, URDS. Excerpts from the USRDS 2005 Annual Data Report. Am J Kidney Dis. 2005;47:S1–S286
  2. Parving HH. Initiation and progression of diabetic nephropathy. N Engl J Med. 1996;335:1682–1683
  3. Krolewski M, Eggers PW, Warram JH. Magnitude of end-stage renal disease in IDDM: a 35 year follow-up study. Kidney Int. 1996;50:2041–2046
  4. Knowler WC, Coresh J, Elston RC, et al. The Family Investigation of Nephropathy and Diabetes (FIND): design and methods. J Diabetes Complications. 2005;19:1–9
  5. Ng DP, Krolewski AS. Molecular genetic approaches for studying the etiology of diabetic nephropathy. Curr Mol Med. 2005;5:509–525
  6. Seaquist ER, Goetz FC, Rich S, et al. Familial clustering of diabetic kidney disease (Evidence for genetic susceptibility to diabetic nephropathy). N Engl J Med. 1989;320:1161–1165
  7. Krolewski AS, Canessa M, Warram JH, et al. Predisposition to hypertension and susceptibility to renal disease in insulin-dependent diabetes mellitus. N Engl J Med. 1988;318:140–145
  8. Orchard TJ, Chang YF, Ferrell RE, et al. Nephropathy in type 1 diabetes: a manifestation of insulin resistance and multiple genetic susceptibilities? (Further evidence from the Pittsburgh Epidemiology of Diabetes Complication Study). Kidney Int. 2002;62:963–970
  9. Mueller PW, Rogus JJ, Cleary PA, et al. Genetics of Kidneys in Diabetes (GoKinD) study: a genetics collection available for identifying genetic susceptibility factors for diabetic nephropathy in type 1 diabetes. J Am Soc Nephrol. 2006;17:1782–1790
  10. Inagi R, Yamamoto Y, Nangaku M, et al. A severe diabetic nephropathy model with early development of nodule-like lesions induced by megsin overexpression in RAGE/iNOS transgenic mice. Diabetes. 2006;55:356–366
  11. Ito T, Tanimoto M, Yamada K, et al. Glomerular changes in the KK-Ay/Ta mouse: a possible model for human type 2 diabetic nephropathy. Nephrology (Carlton). 2006;11:29–35
  12. Levine DZ, Iacovitti M, Robertson SJ, et al. Modulation of single-nephron GFR in the db/db mouse model of type 2 diabetes mellitus. Am J Physiol. 2006;290:R975–R981
  13. Myint KM, Yamamoto Y, Doi T, et al. RAGE control of diabetic nephropathy in a mouse model: effects of RAGE gene disruption and administration of low-molecular weight heparin. Diabetes. 2006;55:2510–2522
  14. Schrijvers BF, Flyvbjerg A, Tilton RG, et al. A neutralizing VEGF antibody prevents glomerular hypertrophy in a model of obese type 2 diabetes, the Zucker diabetic fatty rat. Nephrol Dial Transplant. 2006;21:324–329
  15. Breyer MD, Bottinger E, Brosius FC, et al. Mouse models of diabetic nephropathy. J Am Soc Nephrol. 2005;16:27–45
  16. Chavers BM, Bilous RW, Ellis EN, et al. Glomerular lesions and urinary albumin excretion in type I diabetes without overt proteinuria. N Engl J Med. 1989;320:966–970
  17. Beck JA, Lloyd S, Hafezparast M, et al. Genealogies of mouse inbred strains. Nat Genet. 2000;24:23–25
  18. Wade CM, Daly MJ. Genetic variation in laboratory mice. Nat Genet. 2005;37:1175–1180
  19. Gurley SB, Clare SE, Snow KP, et al. Impact of genetic background on nephropathy in diabetic mice. Am J Physiol. 2006;290:F214–F222
  20. Qi Z, Fujita H, Jin J, et al. Characterization of susceptibility of inbred mouse strains to diabetic nephropathy. Diabetes. 2005;54:2628–2637
  21. Ma LJ, Fogo AB. Model of robust induction of glomerulosclerosis in mice: importance of genetic background. Kidney Int. 2003;64:350–355
  22. Zheng F, Striker GE, Esposito C, et al. Strain differences rather than hyperglycemia determine the severity of glomerulosclerosis in mice. Kidney Int. 1998;54:1999–2007
  23. Qi Z, Whitt I, Mehta A, et al. Serial determination of glomerular filtration rate in conscious mice using FITC-inulin clearance. Am J Physiol Renal Physiol. 2004;286:F590–F596
  24. Hummel KP, Coleman DL, Lane PW. The influence of genetic background on expression of mutations at the diabetes locus in the mouse (I. C57BL-KsJ and C57BL-6J strains). Biochem Genet. 1972;7:1–13
  25. Sharma K, McCue P, Dunn SR. Diabetic kidney disease in the db/db mouse. Am J Physiol. 2003;284:F1138–F1144
  26. Naggert JK, Mu JL, Frankel W, et al. Genomic analysis of the C57BL/Ks mouse strain. Mamm Genome. 1995;6:131–133
  27. Susztak K, Bottinger E, Novetsky A, et al. Molecular profiling of diabetic mouse kidney reveals novel genes linked to glomerular disease. Diabetes. 2004;53:784–794
  28. Cohen MP, Clements RS, Hud E, et al. Evolution of renal function abnormalities in the db/db mouse that parallels the development of human diabetic nephropathy. Exp Nephrol. 1996;4:166–171
  29. Mu JL, Naggert JK, Svenson KL, et al. Quantitative trait loci analysis for the differences in susceptibility to atherosclerosis and diabetes between inbred mouse strains C57BL/6J and C57BLKS/J. J Lipid Res. 1999;40:1328–1335
  30. Pillebout E, Burtin M, Yuan HT, et al. Proliferation and remodeling of the peritubular microcirculation after nephron reduction: association with the progression of renal lesions. Am J Pathol. 2001;159:547–560
  31. Zheng S, Noonan WT, Metreveli NS, et al. Development of late-stage diabetic nephropathy in OVE26 diabetic mice. Diabetes. 2004;53:3248–3257
  32. Festing MF, Simpson EM, Davisson MT, et al. Revised nomenclature for strain 129 mice. Mamm Genome. 1999;10:836
  33. Hartner A, Cordasic N, Klanke B, et al. Strain differences in the development of hypertension and glomerular lesions induced by deoxycorticosterone acetate salt in mice. Nephrol Dial Transplant. 2003;18:1999–2004
  34. Park CW, Kim HW, Ko SH, et al. Accelerated diabetic nephropathy in mice lacking the peroxisome proliferator-activated receptor {alpha}. Diabetes. 2006;55:885–893
  35. Chen A, Sheu LF, Ho YS, et al. Experimental focal segmental glomerulosclerosis in mice. Nephron. 1998;78:440–452
  36. Wang Y, Wang YP, Tay YC, et al. Progressive adriamycin nephropathy in mice: sequence of histologic and immunohistochemical events. Kidney Int. 2000;58:1797–1804
  37. Zheng Z, Schmidt-Ott KM, Chua S, et al. A Mendelian locus on chromosome 16 determines susceptibility to doxorubicin nephropathy in the mouse. Proc Natl Acad Sci U S A. 2005;102:2502–2507
  38. Kimura M, Takahasi H, Ohtake T, et al. Interstrain differences in murine daunomycin-induced nephrosis. Nephron. 1993;63:193–198
  39. Spencer MW, Muhlfeld AS, Segerer S, et al. Hyperglycemia and hyperlipidemia act synergistically to induce renal disease in LDL receptor-deficient BALB mice. Am J Nephrol. 2004;24:20–31
  40. Tay YC, Wang Y, Kairaitis L, et al. Can murine diabetic nephropathy be separated from superimposed acute renal failure?. Kidney Int. 2005;68:391–398
  41. Ikeda H. KK mouse. Diabetes Res Clin Pract. 1994;24(Suppl):S313–S316
  42. Shike T, Gohda T, Tanimoto M, et al. Chromosomal mapping of a quantitative trait locus for the development of albuminuria in diabetic KK/Ta mice. Nephrol Dial Transplant. 2005;20:879–885
  43. Shimasaki Y, Yasue H, Yoshimura M, et al. Association of the missense Glu298Asp variant of the endothelial nitric oxide synthase gene with myocardial infarction. J Am Coll Cardiol. 1998;31:1506–1510
  44. Zanchi A, Moczulski DK, Hanna LS, et al. Risk of advanced diabetic nephropathy in type 1 diabetes is associated with endothelial nitric oxide synthase gene polymorphism. Kidney Int. 2000;57:405–413
  45. Shin Shin Y, Baek SH, Chang KY, et al. Relations between eNOS Glu298Asp polymorphism and progression of diabetic nephropathy. Diabetes Res Clin Pract. 2004;65:257–265
  46. Zhao HJ, Wang S, Cheng H, et al. Endothelial nitric oxide synthase deficiency produces accelerated nephropathy in diabetic mice. J Am Soc Nephrol. 2006;17:2664–2669
  47. Degenhardt TP, Thorpe SR, Baynes JW. Chemical modification of proteins by methylglyoxal. Cell Mol Biol (Noisy-le-grand). 1998;44:1139–1145
  48. Frye EB, Degenhardt TP, Thorpe SR, et al. Role of the Maillard reaction in aging of tissue proteins (Advanced glycation end product-dependent increase in imidazolium cross-links in human lens proteins). J Biol Chem. 1998;273:18714–18719
  49. Niwa T. 3-deoxyglucosone: metabolism, analysis, biological activity, and clinical implication. J Chromatogr B Biomed Sci Appl. 1999;731:23–36
  50. Chen S, Cohen MP, Ziyadeh FN. Amadori-glycated albumin in diabetic nephropathy: pathophysiologic connections. Kidney Int Suppl. 2000;77:S40–S44
  51. Cohen MP. Intervention strategies to prevent pathogenetic effects of glycated albumin. Arch Biochem Biophys. 2003;419:25–30
  52. Vlassara H, Brownlee M, Cerami A. Nonenzymatic glycosylation of peripheral nerve protein in diabetes mellitus. Proc Natl Acad Sci U S A. 1981;78:5190–5192
  53. Wendt T, Tanji N, Guo J, et al. Glucose, glycation, and RAGE: implications for amplification of cellular dysfunction in diabetic nephropathy. J Am Soc Nephrol. 2003;14:1383–1395
  54. Hofmann MA, Drury S, Fu C, et al. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell. 1999;97:889–901
  55. Kislinger T, Fu C, Huber B, et al. N(epsilon)-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J Biol Chem. 1999;274:31740–31749
  56. Lander HM, Tauras JM, Ogiste JS, et al. Activation of the receptor for advanced glycation end products triggers a p21(ras)-dependent mitogen-activated protein kinase pathway regulated by oxidant stress. J Biol Chem. 1997;272:17810–17814
  57. Sorci G, Riuzzi F, Agneletti AL, et al. S100B causes apoptosis in a myoblast cell line in a RAGE-independent manner. J Cell Physiol. 2004;199:274–283
  58. Wendt TM, Tanji N, Guo J, et al. RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol. 2003;162:1123–1137
  59. Yamamoto Y, Kato I, Doi T, et al. Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. J Clin Invest. 2001;108:261–268
  60. Dunn SR, Qi Z, Bottinger EP, et al. Utility of endogenous creatinine clearance as a measure of renal function in mice. Kidney Int. 2004;65:1959–1967
  61. Jung K, Wesslau C, Priem F, et al. Specific creatinine determination in laboratory animals using the new enzymatic test kit ″Creatinine-PAP. J Clin Chem Clin Biochem. 1987;25:357–361
  62. Meyer MH, Meyer RA, Gray RW, et al. Picric acid methods greatly overestimate serum creatinine in mice: more accurate results with high-performance liquid chromatography. Anal Biochem. 1985;144:285–290
  63. Yuen PS, Dunn SR, Miyaji T, et al. A simplified method for HPLC determination of creatinine in mouse serum. Am J Physiol. 2004;286:F1116–F1119
  64. Kakoki M, Takahashi N, Jennette JC, et al. Diabetic nephropathy is markedly enhanced in mice lacking the bradykinin B2 receptor. Proc Natl Acad Sci U S A. 2004;101:13302–13305
  65. Hrabe de Angelis MH, Flaswinkel H, Fuchs H, et al. Genome-wide, large-scale production of mutant mice by ENU mutagenesis. Nat Genet. 2000;25:444–447
  66. Weber JS, Salinger A, Justice MJ. Optimal N-ethyl-N-nitrosourea (ENU) doses for inbred mouse strains. Genesis. 2000;26:230–233
  67. Justice MJ, Noveroske JK, Weber JS, et al. Mouse ENU mutagenesis. Hum Mol Genet. 1999;8:1955–1963
  68. Favor J. Mechanisms of mutation induction in germ cells of the mouse as assessed by the specific locus test. Mutat Res. 1999;428:227–236
  69. Beier DR. Sequence-based analysis of mutagenized mice. Mamm Genome. 2000;11:594–597
  70. Russell WL, Kelly EM, Hunsicker PR, et al. Specific-locus test shows ethylnitrosourea to be the most potent mutagen in the mouse. Proc Natl Acad Sci U S A. 1979;76:5818–5819
  71. Concepcion D, Seburn KL, Wen G, et al. Mutation rate and predicted phenotypic target sizes in ethylnitrosourea-treated mice. Genetics. 2004;168:953–959
  72. Cordes SP. N-ethyl-n-nitrosourea mutagenesis: boarding the mouse mutant express. Microbiol Mol Biol Rev. 2005;69:426–439
  73. Nolan PM, Hugill A, Cox RD. ENU mutagenesis in the mouse: application to human genetic disease. Brief Funct Genomic Proteomic. 2002;1:278–289
  74. Nolan PM, Peters J, Strivens M, et al. A systematic, genome-wide, phenotype-driven mutagenesis programme for gene function studies in the mouse. Nat Genet. 2000;25:440–443
  75. Nadeau JH, Frankel WN. The roads from phenotypic variation to gene discovery: mutagenesis versus QTLs. Nat Genet. 2000;25:381–384
  76. Su LK, Kinzler KW, Vogelstein B, et al. Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene. Science. 1992;256:668–670
  77. Vitaterna MH, King DP, Chang AM, et al. Mutagenesis and mapping of a mouse gene, Clock, essential for circadian behavior. Science. 1994;264:719–725
  78. Imperatore G, Knowler WC, Pettitt DJ, et al. Segregation analysis of diabetic nephropathy in Pima Indians. Diabetes. 2000;49:1049–1056
  79. Vardarli I, Baier LJ, Hanson RL, et al. Gene for susceptibility to diabetic nephropathy in type 2 diabetes maps to 18q22.3-23. Kidney Int. 2002;62:2176–2183
  80. Wang J, Takeuchi T, Tanaka S, et al. A mutation in the insulin 2 gene induces diabetes with severe pancreatic beta-cell dysfunction in the Mody mouse. J Clin Invest. 1999;103:27–37
  81. Mathews CE, Langley SH, Leiter EH. New mouse model to study islet transplantation in insulin-dependent diabetes mellitus. Transplantation. 2002;73:1333–1336
  82. Tchekvena EE, Rinchik EM, Polosukhina D, et al. A sensitized screen of ENU mutagenized mice identifies dominant mutants predisposed to diabetic nephropathy. J Am Soc Nephrol. In press.
  83. Flint J, Valdar W, Shifman S, et al. Strategies for mapping and cloning quantitative trait genes in rodents. Nat Rev Genet. 2005;6:271–286
  84. Vitt U, Gietzen D, Stevens K, et al. Identification of candidate disease genes by EST alignments, synteny, and expression and verification of Ensembl genes on rat chromosome 1q43-54. Genome Res. 2004;14:640–650
  85. Clee SM, Yandell BS, Schueler KM, et al. Positional cloning of Sorcs1, a type 2 diabetes quantitative trait locus. Nat Genet. 2006;38:688–693
  86. Klein RF, Allard J, Avnur Z, et al. Regulation of bone mass in mice by the lipoxygenase gene Alox15. Science. 2004;303:229–232
  87. Wang X, Ria M, Kelmenson PM, et al. Positional identification of TNFSF4, encoding OX40 ligand, as a gene that influences atherosclerosis susceptibility. Nat Genet. 2005;37:365–372
  88. Stoll M, Kwitek-Black AE, Cowley AW, et al. New target regions for human hypertension via comparative genomics. Genome Res. 2000;10:473–482
  89. Sugiyama F, Churchill GA, Higgins DC, et al. Concordance of murine quantitative trait loci for salt-induced hypertension with rat and human loci. Genomics. 2001;71:70–77
  90. Korstanje R, DiPetrillo K. Unraveling the genetics of chronic kidney disease using animal models. Am J Physiol. 2004;287:F347–F352
  91. Marshall JD, Mu JL, Cheah YC, et al. The AXB and BXA set of recombinant inbred mouse strains. Mamm Genome. 1992;3:669–680
  92. Peirce JL, Lu L, Gu J, et al. A new set of BXD recombinant inbred lines from advanced intercross populations in mice. BMC Genet. 2004;5:7
  93. Williams RW, Gu J, Qi S, et al. The genetic structure of recombinant inbred mice: high-resolution consensus maps for complex trait analysis. Genome Biol. 2001;2:1–18

 Supported by National Institutes of Health grant U01 DK61018.

PII: S0270-9295(07)00002-2

doi: 10.1016/j.semnephrol.2007.01.001

Seminars in Nephrology
Volume 27, Issue 2 , Pages 237-247 , March 2007

Article Tools

* Image Usage & Resolution